Top

Published in:

Open Access 01-12-2022 | Myocardial Infarction | Study protocol

Single vs. double intracoronary injection of mesenchymal stromal cell after acute myocardial infarction: the study protocol from a randomized clinical trial: BOOSTER-TAHA7 trial

Authors: Armin Attar, Fatemeh Nouri, Arash Yazdanshenas, Kamran Hessami, Massoud Vosough, Alireza Abdi-Ardekani, Peyman Izadpanah, Mani Ramzi, Javad Kojouri, Gholamreza Pouladfar, Ahmad Monabati

Published in: Trials | Issue 1/2022

Abstract

Background

Meta-analysis from previous studies have shown that treatment with mesenchymal stromal cell (MCSs) may increase the left ventricular ejection fraction (LVEF) after acute myocardial infarction (AMI) by 3.84%, and the effect is greater in those who are not aged and have developed a reduced LVEF. However, it seems that MSC transplantation does its effect through an indirect paracrine effect, and direct differentiation to the cardiomyocytes does not occur. Therefore, it can be hypothesized that this paracrine effect would be augmented if repeated doses of MSC are transplanted. This study is conducted to compare single vs. double injection of MSCs.

Methods

This is a single-blind, randomized, multicenter trial aiming to determine whether intracoronary infusion of double doses of umbilical cord-derived Wharton’s jelly MSCs (WJ-MSCs) improves LVEF more after AMI compared to single administration. Sixty patients 3 to 7 days after AMI will be enrolled. The patients should be under 65 years old and have a severe impairment in LV function (LVEF < 40%). They will be randomized to three arms receiving single or double doses of intracoronary infusion of WJ-MSCs or placebo. The primary endpoint of this study is assessment of improvement in LVEF at 6-month post intervention as compared to the baseline.

Discussion

This investigation will help to determine whether infusion of booster (second) dose of intracoronary WJ-MSCs in patients with AMI will contribute to increasing its effect on the improvement of myocardial function.

Trial registration

Iranian Registry of Clinical Trials (www.IRCT.ir) IRCT20201116049408N1. Registered on November 26 2020

Organization WH. The global burden of disease: 2004 update. Geneva: World Health Organization; 2008.

Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D'Agostino RB, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation. 2008;118(20):2057–62. https://doi.org/10.1161/CIRCULATIONAHA.108.784215.CrossRefPubMedPubMedCentral

Hellermann JP, Jacobsen SJ, Gersh BJ, Rodeheffer RJ, Reeder GS. Heart failure after myocardial infarction: a review. Am J Med. 2002;113(4):324–30. https://doi.org/10.1016/S0002-9343(02)01185-3.CrossRefPubMed

Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–e220. https://doi.org/10.1161/CIR.0b013e31823ac046.CrossRefPubMed

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134(13):e282–93. https://doi.org/10.1161/CIR.0000000000000435.CrossRefPubMed

Juillière Y, Cambou JP, Bataille V, Mulak G, Galinier M, Gibelin P, et al. Heart failure in acute myocardial infarction: a comparison between patients with or without heart failure criteria from the FAST-MI registry. Rev Esp Cardiol (Engl Ed). 2012;65(4):326–33. https://doi.org/10.1016/j.recesp.2011.10.027.CrossRef

Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JM, Warnica JW, et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol. 2003;42(8):1446–53. https://doi.org/10.1016/S0735-1097(03)01057-X.CrossRefPubMed

Juillière Y, Cambou JP, Bataille V, Mulak G, Galinier M, Gibelin P, et al. Heart failure in acute myocardial infarction: a comparison between patients with or without heart failure criteria from the FAST-MI registry. Rev Esp Cardiol (English Edition). 2012;65(4):326–33. https://doi.org/10.1016/j.rec.2011.10.028.CrossRef

Braunwald E. Cell-based therapy in cardiac regeneration: an overview. Circ Res. 2018;123(2):132–7. https://doi.org/10.1161/CIRCRESAHA.118.313484.CrossRefPubMed

10.

Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, Hutcheson KA, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med. 1998;4(8):929–33. https://doi.org/10.1038/nm0898-929.CrossRefPubMed

11.

Leor J, Patterson M, Quinones MJ, Kedes LH, Kloner RA. Transplantation of fetal myocardial tissue into the infarcted myocardium of rat. A potential method for repair of infarcted myocardium? Circulation. 1996;94(9 Suppl):Ii332–6.PubMed

12.

Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410(6829):701–5. https://doi.org/10.1038/35070587.CrossRefPubMed

13.

Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7(4):430–6. https://doi.org/10.1038/86498.CrossRefPubMed

14.

Menasché P, Hagège AA, Scorsin M, Pouzet B, Desnos M, Duboc D, et al. Myoblast transplantation for heart failure. Lancet. 2001;357(9252):279–80. https://doi.org/10.1016/S0140-6736(00)03617-5.CrossRefPubMed

15.

Assmus B, Schächinger V, Teupe C, Britten M, Lehmann R, Döbert N, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation. 2002;106(24):3009–17. https://doi.org/10.1161/01.CIR.0000043246.74879.CD.CrossRefPubMed

16.

Williams A, Hare J. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011;109(8):923–40. https://doi.org/10.1161/CIRCRESAHA.111.243147.CrossRefPubMedPubMedCentral

17.

Houtgraaf JH, den Dekker WK, van Dalen BM, Springeling T, de Jong R, van Geuns RJ, et al. First experience in humans using adipose tissue–derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012;59(5):539–40. https://doi.org/10.1016/j.jacc.2011.09.065.CrossRefPubMed

18.

Houtgraaf JH, den Dekker WK, van Dalen BM, Springeling T, de Jong R, van Geuns RJ, et al. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012;59(5):539–40. https://doi.org/10.1016/j.jacc.2011.09.065.CrossRefPubMed

19.

Karantalis V, Schulman I, Balkan W, Hare J. Allogeneic cell therapy a new paradigm in therapeutics. Circ Res. 2015;116(1):12–5. https://doi.org/10.1161/CIRCRESAHA.114.305495.CrossRefPubMedPubMedCentral

20.

Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369–79. https://doi.org/10.1001/jama.2012.25321.CrossRefPubMedPubMedCentral

21.

Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311(1):62–73. https://doi.org/10.1001/jama.2013.282909.CrossRefPubMedPubMedCentral

22.

Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306(19):2110–9. https://doi.org/10.1001/jama.2011.1670.CrossRefPubMedPubMedCentral

23.

Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012;308(22):2380–9. https://doi.org/10.1001/jama.2012.28726.CrossRefPubMedPubMedCentral

24.

Fisher SA, Zhang H, Doree C, Mathur A, Martin-Rendon E. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2015;2015(9):Cd006536.PubMedCentral

25.

Gao LR, Chen Y, Zhang NK, Yang XL, Liu HL, Wang ZG, et al. Intracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial. BMC Med. 2015;13(1):162. https://doi.org/10.1186/s12916-015-0399-z.CrossRefPubMedPubMedCentral

26.

Attar A, Bahmanzadegan Jahromi F, Kavousi S, Monabati A, Kazemi A. Mesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trials. Stem Cell Res Ther. 2021;12(1):600. https://doi.org/10.1186/s13287-021-02667-1.CrossRefPubMedPubMedCentral

27.

Hong K, Guo Y, Li Q-H, Cao P, Al-Maqtari T, Vajravelu B, et al. c-kit+ cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart. PLoS One. 2014;9(5):e96725. https://doi.org/10.1371/journal.pone.0096725.CrossRefPubMedPubMedCentral

28.

Cai L, Johnstone B, Cook T, Tan J, Fishbein M, Chen P-S, et al. IFATS collection: human adipose tissue-derived stem cells induce angiogenesis and nerve sprouting following myocardial infarction, in conjunction with potent preservation of cardiac function. Stem cells (Dayton, Ohio). 2008;27:230–7.CrossRef

29.

Sanganalmath S, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013;113(6):810–34. https://doi.org/10.1161/CIRCRESAHA.113.300219.CrossRefPubMedPubMedCentral

Title: Single vs. double intracoronary injection of mesenchymal stromal cell after acute myocardial infarction: the study protocol from a randomized clinical trial: BOOSTER-TAHA7 trial
Authors: Armin Attar
Fatemeh Nouri
Arash Yazdanshenas
Kamran Hessami
Massoud Vosough
Alireza Abdi-Ardekani
Peyman Izadpanah
Mani Ramzi
Javad Kojouri
Gholamreza Pouladfar
Ahmad Monabati
Publication date: 01-12-2022
Publisher: BioMed Central
Keyword: Myocardial Infarction
Published in: Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI: https://doi.org/10.1186/s13063-022-06276-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Single vs. double intracoronary injection of mesenchymal stromal cell after acute myocardial infarction: the study protocol from a randomized clinical trial: BOOSTER-TAHA7 trial

Abstract

Background

Methods

Discussion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2022

A protocol for monitoring fidelity of a preconception-life course intervention in a middle-income setting: the Healthy Life Trajectories Initiative (HeLTI), South Africa

A home-based, multidisciplinary liver optimisation programme for the first 28 days after an admission for acute-on-chronic liver failure (LivR well): a study protocol for a randomised controlled trial

Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease

Health belief model for empowering parental toothbrushing and sugar intake control in reducing early childhood caries among young children—study protocol for a cluster randomized controlled trial

Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments

Minding the Baby versus usual care: study protocol for a quasi-cluster-randomized controlled study in Denmark of an early interdisciplinary home-visiting intervention for families at increased risk for adversity